Consensus guidelines for the diagnosis and treatment of multiple sclerosis

References

• Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965;122:552-68
   PubMed Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302
   PubMed Web of Science ®Google Scholar
• Charil A, Yousry TA, Rovaris M, et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of ‘no better explanation’. Lancet Neurol 2006;5:841-52
   PubMed Web of Science ®Google Scholar
• Kelly SB, Chaila E, Kinsella K, et al. Using atypical symptoms and red flags to identify non-demyelinating disease. J Neurol Neurosurg Psychiatry 2012;83:44-8
   PubMed Web of Science ®Google Scholar
• De Seze J. Atypical forms of optic neuritis. Rev Neurol (Paris) 2012;168:697-701
   PubMed Web of Science ®Google Scholar
• Giesser BS. Diagnosis of multiple sclerosis. Neurol Clin 2011;29:381-8
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA. The role of magnetic resonance imaging in the study of multiple sclerosis: diagnosis, prognosis and understanding disease pathophysiology. Acta Neurol Belg 2011;111:89-98
   PubMed Web of Science ®Google Scholar
• Palace J. Guidelines for differential diagnosis of suspected multiple sclerosis. Nat Clin Pract Neurol 2009;5:134-5
   PubMedGoogle Scholar
• Brinar VV, Habek M. Rare infections mimicking MS. Clin Neurol Neurosurg 2010;112:625-8
   PubMed Web of Science ®Google Scholar
• Köhler W. Diagnostic algorithm for the differentiation of leukodystrophies in early MS. J Neurol 2008;255(Suppl 6):123-6
   PubMedGoogle Scholar
• Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000;(4):CD001331
   PubMedGoogle Scholar
• Weinshenker BG, O’Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878-86
   PubMed Web of Science ®Google Scholar
• Magaña SM, Keegan BM, Weinshenker BG, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 2011;68:870--878
   PubMed Web of Science ®Google Scholar
• Habek M, Barun B, Puretić Z, Brinar VV. Treatment of steroid unresponsive relapse with plasma exchange in aggressive multiple sclerosis. Ther Apher Dial 2010;14:298-302
   PubMed Web of Science ®Google Scholar
• Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004;63:1081-3
   PubMed Web of Science ®Google Scholar
• Llufriu S, Castillo J, Blanco Y, et al. Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months. Neurology 2009;73:949-53
   PubMed Web of Science ®Google Scholar
• Trebst C, Reising A, Kielstein JT, et al. Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif 2009;28:108-15
   PubMed Web of Science ®Google Scholar
• Yücesan C, Arslan O, Arat M, et al. Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: review of 50 cases. Transfus Apher Sci 2007;36:103-7
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Karnes WE, Bartleson JD, et al. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 1993;43:1100-4
   PubMed Web of Science ®Google Scholar
• Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;76:294-300
   PubMed Web of Science ®Google Scholar
• Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999;353:964-9
   PubMed Web of Science ®Google Scholar
• Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993;116(Pt 1):135-46
   Google Scholar
• Rocca MA, Agosta F, Sormani MP, et al. A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol 2008;255:683-91
   PubMed Web of Science ®Google Scholar
• Tintoré M, Rovira A, Río J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006;67:968-72
   PubMed Web of Science ®Google Scholar
• Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131(Pt 3):808-17
   PubMed Web of Science ®Google Scholar
• Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281-8
   PubMed Web of Science ®Google Scholar
• Swanton JK, Fernando KT, Dalton CM, et al. Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis. Mult Scler 2010;16:156-65
   PubMed Web of Science ®Google Scholar
• Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol;65:727-32
   PubMed Web of Science ®Google Scholar
• Patrucco L, Rojas JI, Cristiano E. Assessing the value of spinal cord lesions in predicting development of multiple sclerosis in patients with clinically isolated syndromes. J Neurol 2011;259:1317-20
   PubMed Web of Science ®Google Scholar
• Mowry EM, Deen S, Malikova I, et al. The onset location of multiple sclerosis predicts the location of subsequent relapses. J Neurol Neurosurg Psychiatry 2009;80:400-3
   PubMed Web of Science ®Google Scholar
• Villar LM, García-Barragán N, Sádaba MC, et al. Accuracy of CSF and MRI criteria for dissemination in space in the diagnosis of multiple sclerosis. J Neurol Sci 2008;266:34-7
   PubMed Web of Science ®Google Scholar
• Morrow SA, Fraser JA, Nicolle D, et al. Predicting conversion to MS – the role of a history suggestive of demyelination. Can J Neurol Sci 2010;37:488-91
   PubMed Web of Science ®Google Scholar
• Brex PA, Ciccarelli O, O’Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-64
   PubMed Web of Science ®Google Scholar
• Vercellino M, Romagnolo A, Mattioda A, et al. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants. Acta Neurol Scand 2009;119:126-30
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Barkhof F, et al.; Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82
   PubMed Web of Science ®Google Scholar
• Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9
   PubMed Web of Science ®Google Scholar
• Comi G, Martinelli V, Rodegher M, et al.; PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-11
   PubMed Web of Science ®Google Scholar
• O’connor P, Kinkel RP, Kremenchutzky M. Efficacy of IM intereferon beta 1 a in patients with CIS analysis of subgroups based on new risk criteria. Multiple Sclerosis 2009;15:728-34
   PubMed Web of Science ®Google Scholar
• Clerico M, Faggiano F, Palace J, et al. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev 2008;(2):CD005278
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• The PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• Rice GP, Incorvaia B, Munari L, et al. Interferon in relapsing–remitting multiple sclerosis. Cochrane Database Syst Rev 2001;(4):CD002002
   PubMedGoogle Scholar
• Kappos L, Radue EW, O’Connor P, et al.; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al.; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• Del Santo F, Maratea D, Fadda V, et al. Treatments for relapsing–remitting multiple sclerosis: summarising current information by network meta-analysis. Eur J Clin Pharmacol 2012;68:441-8
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al.; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al.; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
   PubMed Web of Science ®Google Scholar
• Hutchinson M, Kappos L, Calabresi PA, et al.; AFFIRM and SENTINEL Investigators. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009;256:405-15
   PubMed Web of Science ®Google Scholar
• Pucci E, Giuliani G, Solari A, et al. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2011;(10):CD007621
   PubMed Web of Science ®Google Scholar
• Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012;18:143-52
   PubMed Web of Science ®Google Scholar
• Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011;10:745-58
   PubMed Web of Science ®Google Scholar
• Hellwig K, Gold R. Progressive multifocal leukoencephalopathy and natalizumab. J Neurol 2011;258:1920-8
   PubMed Web of Science ®Google Scholar
• Bozic C, Richman S, Plavina T, et al. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011;70:742-50
   PubMed Web of Science ®Google Scholar
• Plavina T, Berman M, Njenga M, et al. Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma. J Clin Virol 2012;53:65-71
   PubMed Web of Science ®Google Scholar
• Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68:295-303
   PubMed Web of Science ®Google Scholar
• European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-7
   PubMed Web of Science ®Google Scholar
• Kappos L, Polman C, Pozzilli C, et al.; European Study Group in Interferon beta-1b in Secondary–Progressive MS. Final analysis of the European multicenter trial on IFNbeta-1b in secondary–progressive MS. Neurology 2001;57:1969-75
   PubMed Web of Science ®Google Scholar
• Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788-95
   PubMed Web of Science ®Google Scholar
• Cohen JA, Cutter GR, Fischer JS, et al.; IMPACT Investigators. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-87
   PubMed Web of Science ®Google Scholar
• Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-504
   PubMed Web of Science ®Google Scholar
• Hartung HP, Gonsette R, König N, et al.; Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-25
   PubMed Web of Science ®Google Scholar
• Zipoli V, Portaccio E, Hakiki B, et al. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. J Neurol Sci 2008;266:25-30
   PubMed Web of Science ®Google Scholar
• Zephir H, de Seze J, Duhamel A, et al. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 2004;218:73-7
   PubMed Web of Science ®Google Scholar
• Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37:30-40
   PubMed Web of Science ®Google Scholar
• Frohman EM, Brannon K, Racke MK, Hawker K. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 2004;27:80-3
   PubMed Web of Science ®Google Scholar
• Ahrens N, Salama A, Haas J. Mycophenolate–mofetil in the treatment of refractory multiple sclerosis. J Neurol 2001;248:713-14
   PubMed Web of Science ®Google Scholar
• Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003;60:44-51
   PubMed Web of Science ®Google Scholar
• Montalban X. Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis. Mult Scler 2004;10(Suppl 1):S62,62-4
   Google Scholar
• Wolinsky JS, Narayana PA, O’Connor P, et al.; PROMiSe Trial Study Group. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24
   PubMed Web of Science ®Google Scholar
• Cadavid D, Kim S, Peng B, et al. Clinical consequences of MRI activity in treated multiple sclerosis. Mult Scler 2011;17:1113-21
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA. MR imaging of multiple sclerosis. Radiology 2011;259:659-81
   PubMed Web of Science ®Google Scholar
• Gauthier SA, Glanz BI, Mandel M, et al. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study. J Neurol Sci 2009;284:116-19
   PubMed Web of Science ®Google Scholar
• Freedman MS, Cohen B, Dhib-Jalbut S, et al. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Curr Med Res Opin 2009;25:2459-70
   PubMed Web of Science ®Google Scholar
• Healy BC, Glanz BI, Stankiewicz J, et al. A method for evaluating treatment switching criteria in multiple sclerosis. Mult Scler 2010;16:1483-9
   PubMed Web of Science ®Google Scholar
• Sormani MP, Li DK, Bruzzi P, et al. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology 2011;77:1684-90
   PubMed Web of Science ®Google Scholar
• Prosperini L, Borriello G, De Giglio L, et al. Management of breakthrough disease in patients with multiple sclerosis: when an increasing of interferon beta dose should be effective? BMC Neurol 2011;11:26
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G, et al.; EVIDENCE Study Group. EVidence of Interferon Dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002;59:1496-506
   PubMed Web of Science ®Google Scholar
• Durelli L, Verdun E, Barbero P, et al.; Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60
   PubMed Web of Science ®Google Scholar
• Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 2009;23:379-96
   PubMed Web of Science ®Google Scholar
• Aarskog NK, Marøy T, Myhr KM, et al. Antibodies against interferon-beta in multiple sclerosis. J Neuroimmunol 2009;212:148-50
   PubMed Web of Science ®Google Scholar
• Farrell RA, Espasandin M, Lakdawala N, et al. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice. Mult Scler 2011;17:1333-40
   PubMed Web of Science ®Google Scholar
• Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010;9:740-50
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Mellgren SI, Svenningsson A, et al. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 2009;8:519-29
   PubMed Web of Science ®Google Scholar
• Ravnborg M, Sørensen PS, Andersson M, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol 2010;9:672-80
   PubMed Web of Science ®Google Scholar
• Prosperini L, Giannì C, Leonardi L, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler 2012;18:64-71
   PubMed Web of Science ®Google Scholar
• Lanzillo R, Quarantelli M, Bonavita S, et al. Natalizumab vs interferon beta 1a in relapsing–remitting multiple sclerosis: a head-to-head retrospective study. Acta Neurol Scand 2011;126:306-14
   PubMed Web of Science ®Google Scholar
• Horga A, Castillo J, Rio J, et al. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. Rev Neurol 2011;52:321-30
   PubMed Web of Science ®Google Scholar
• Fernández-Megía MJ, Casanova B, Magraner MJ, et al. Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis. Farm Hosp 2011;35:75-9
   PubMedGoogle Scholar
• Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology 2004;63(12 Suppl 6):S8-14
   PubMed Web of Science ®Google Scholar
• Khan OA, Zvartau-Hind M, Caon C, et al. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler 2001;7:185-8
   PubMed Web of Science ®Google Scholar